MedTrace Logo

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

NCT07117877 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2025-08-28

No results posted yet for this study

Summary

This study is a Prospective, Single-arm, Phase II clinical trial. The purpose of this study is to find out if taking Etoposide Capsules combined With Bevacizumab and Iparomlimab and Tuvonralimab is safe and works well for people with platinum-resistant or platinum refractory ovarian cancer . Researchers will look at the Progression-Free Survival, Objective Response Rate, Overall Survival, safety, and any side effects.

Conditions

  • Platinum Resistant Ovarian Cancer
  • Platinum Refractory Epithelial Ovarian Cancer
  • Ovarian Cancer (OvCa)

Interventions

DRUG

Etoposide Capsules

50 mg(25mg/pill, 2 pills at a time) orally, qd, days 1 to 14, per cycle

DRUG

Bevacizumab

7.5mg/kg, i.v, q3w

DRUG

Iparomlimab and Tuvonralimab (QL1706)

5mg/kg, i.v., q3w

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-15
Primary Completion
2026-08-31
Completion
2027-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07117877 on ClinicalTrials.gov